DAY 3 Saturday, May 14, 2022

E : English
BS : Breakfast Seminar LS : Luncheon Seminar

PACIFICO Yokohama North

7:30 8:00 9:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:30

Room 1 (1F G5+G6) / Web Room 1

- 9:00~11:00 **Symposium 4** (E)
  GVHD from Here to the Future: New Understandings of Pathogenesis and Further Evolution of Treatment
  Kenichi Matsuoka, Yoshihiro Inamoto P.13
- 11:30~12:20 **LS15**
  New Treatment Strategies for Chronic GVHD
  Speaker: Noriko Doki
  Chair: Keita Kirito
  (Janssen Pharmaceutical K.K.)
- 12:30~13:00 **Awards ceremony**
- 13:05~13:25 JSTCT Prize Commemorative Lecture P.13
- 13:30~14:15 **Plenary Session**
  Junji Tanaka
  Yoshiki Akatsuka P.14
- 14:30~16:10 **Symposium 5**
  Molecular Mechanisms of Relapse after Transplantation/ Immuno-cell Therapy
  Toshihiro Miyamoto, Kinuko Mitani
  (Astellas Pharma Inc.) P.14

Room 2 (1F G7) / Web Room 2

- 9:00~10:15 The allied organizations forum for promoting hematopoietic stem cell transplantation P.15
- 10:20~11:05 **Special Message**
  Story I want to tell you at the dawn of the innovative cellular therapies
  Speaker: Shinichiro Okamoto
  Chair: Takanori Teshima P.15
- 11:30~12:20 **LS16**
  Reconsideration of maintenance therapy for transplant-eligible patients with multiple myeloma
  Speaker: Tomohiko Kamimura
  Chair: Shinsuke Iida
  (Takeda Pharmaceutical Company Limited)
- 14:30~16:00 **Symposium 6** (E)
  Cutting Edge of CBT 2022
  Satoshi Takahashi
  Shuichi Taniguchi P.16

Room 3 (1F G8) / Web Room 3

- 9:00~10:30 **Workshop 5**
  Patient Anger; How do you perceive it and how do you relate to it?
  Susumu Omae, Noriko Doki P.16
- Is Up-front ASCT still necessary for NDMM who achieved MRD-negativity after induction treatment?
  Nobuhiro Tsukada
- 11:30~12:20 **LS17**
  Multidisciplinary approach for oncofertility care
  Speaker: Chie Watanabe
  Chair: Tomoko Yashima
  (Chugai Pharmaceutical Co., Ltd.)
- 14:15~16:10 **Nursing Symposium**
  CAR-T Cell Therapy
  Tomoko Sato
  Yoko Yamamoto P.17

Room 4 (3F G301+G302) / Web Room 4

- 8:00~8:50 **BS1**
  Genomic analysis of B-cell acute lymphoblastic leukemia and its clinical relevance
  Speaker: Koichi Takahashi
  Chair: Seishi Ogawa
  (Otsuka Pharmaceutical Co., Ltd.)
- 9:00~10:30 **Round table 2**
  Tips on how to success CBT
  Takaaki Konuma
  Hisashi Yamamoto P.17
- 10:35~11:10 Pros・Cons 3 P.18
- 11:30~12:20 **LS18**
  Approaches to improve outcomes for *FLT3*-Mutated AML
  Speakers: Shinsuke Takagi
  Junichi Sugita
  Chair: Hitoshi Kiyoi
  (Astellas Pharma Inc.)
- 14:30~15:30 **Workshop 6**
  ATL: Advances in Pathological Analysis and Treatment Strategies
  Kaoru Uchimaru P.18

Room 5 (3F G303) / Web Room 5

- 9:00~10:00 **Workshop 7**
  COVID-19 Pandemic
  Akihito Shinohara P.18
- 10:10~11:10 **Workshop 8**
  Conditioning Regimen: Appropriateness in an Era of Diversity
  Kaichi Nishiwaki
  Makoto Onizuka P.19
- 11:30~12:20 **LS19**
  How do we consider the treatment strategies to achieve MRD negativity with Sorafenib in regimen?
  Speaker: Hiroyuki Takamatsu
  Nobuhiro Tsukada
  Chair: Yoshinobu Kanda
  (Sanofi K.K.)
- 14:30~16:00 **HCTC Workshop**
  Support for donors from far away / How to cooperate with other facilities
  Yasunori Ueda, Yuki Nakaya P.19

Room 6 (3F G304) / Web Room 6

- 8:00~8:50 **BS2**
  Cutting edge of molecular target therapy for CML
  Speaker: Emiko Sakaida
  Chair: Itaru Matsumura
  (Novartis Pharma K.K.)
- 9:00~9:48 Oral presentation 28
  AA
  Takeshi Kobayashi P.108
- 10:10~11:10 Oral presentation 29
  Late Complication 2
  Chikako Ohwada P.109
- 11:30~12:20 **LS20**
  Hematopoietic stem cell transplantation ~Update of the prevention and treatment for invasive fungal infection~
  Speaker: Yuki Mori
  Chair: Shinya Kimura
  (Pfizer Japan Inc.)
- 14:30~15:10 GVHD Registry session
- 15:15~16:10 National Survey News

Room 7 (4F G401) / Web Room 7

- 8:00~8:50 **BS3**
  Tips for Successful Use of CAR-T Therapy in DLBCL
  Speaker: Hideki Goto
  Chair: Takanori Teshima
  (Bristol-Myers Squibb K.K.)
- 9:00~10:00 Oral presentation 30
  HCTC
  Hideki Goto P.110
- 10:10~11:10 Oral presentation 31
  SOS/VOD
  Kimikazu Yakushijin P.111
- 11:30~12:20 **LS21**
  Management of fungal infections in hematopoietic cell transplantation
  Speaker: Hisakazu Nishimori
  Chair: Takehiko Mori
  (Sumitomo Pharma Co., Ltd.)
- 15:00~16:00 Oral presentation 32
  HSC/Immununology
  Yoshio Katayama P.112

Room 8 (4F G402) / Web Room 8

- 9:00~10:00 Oral presentation 33 (E)
  Late Complication 1
  Hideki Nakasone P.113
- 10:10~11:10 Oral presentation 34 (E)
  CAR-T Cell Therapy 2
  Haruko Tashiro P.114
- 11:30~12:20 **LS22**
  A Paradigm Shift in the Treatment of AML
  Speaker: Junya Kanda
  Chair: Koichi Akashi
  (AbbVie GK)
- 14:20~15:08 Oral presentation 35 (E)
  CAR-T Cell Therapy 3
  Nobuhiro Tsukada P.116
- 15:13~16:13 Oral presentation 36 (E)
  Transplant Immunity
  Tomomi Toubai P.118

Room 9 (4F G403) / Web Room 9

- 9:00~10:00 Oral presentation 37
  Early Complication
  Sigesaburo Miyakoshi P.119
- 10:10~11:10 Oral presentation 38
  COVID-19
  Masamichi Isobe P.120
- 11:30~12:20 **LS23**
  New Value of Proteasome Inhibitors in Relapsed/ Refractory Multiple Myeloma
  Speakers: Yusuke Furukawa, Tadao Ishida
  Chairs: Shuichi Taniguchi, Toshihiro Miyamoto
  (ONO PHARMACEUTICAL CO.,LTD.)
- 14:20~15:20 Oral presentation 39
  Prognostic Factor
  Hikaru Kobayashi P.121
- 15:25~16:13 Oral presentation 40
  MPN
  Takeshi Kondo P.122

Room 10 (4F G404) / Web Room 10

- 9:00~10:00 Oral presentation 41
  Cell Therapy: Basical Research
  Yozo Nakazawa P.123
- 10:10~11:10 Oral presentation 42
  Stem Cell Mobilization and Harvest
  Ryuji Tanosaki P.124
- 11:30~12:20 **LS24**
  Recent advances in treatment strategies for DLBCL
  Speaker: Koji Kato
  Chair: Masao Matsuoka
  (Symbio Pharmaceuticals Limited)

Room 11 (4F G412+G413) / Web Room 11

- 11:30~12:20 **LS25**
  How to select appropriate conditioning regimen
  Speaker: Yoshimitsu Shimomura
  Chair: Hisashi Yamamoto
  (Otsuka Pharmaceutical Co., Ltd.)

Room 12 (4F G414+G415) / Web Room 12

- 8:00~8:50 **BS4**
  Indication of pleritaxfor based on the real-world data
  Speaker: Yasuyuki Arai
  Chair: Junji Tanaka
  (Sanofi K.K.)
- 11:30~12:20 **LS26**
  Recent advances and future perspectives in CAR T-cell therapy for B-cell non-Hodgkin lymphomas
  Speaker: Shinichi Makita
  Chair: Kimikazu Matsumoto
  (DAIICHI SANKYO COMPANY, LIMITED)

Room 13 (4F G416+G417) / Web Room 13

- 8:00~8:50 **BS5**
  B-ALL frontline treatment strategy-Current status and future perspective in 2022
  Speaker: Shuichi Mizuta
  Chair: Koji Nagatuji
  (Medical Affairs, AMGEN K.K. / Medical Affairs, Astellas Pharma Inc.)
- 11:30~12:20 **LS27**
  The utility of measurable residual disease in multiple myeloma
  Speaker: Hayato Maruoka
  Chair: Shigeru Chiba
  (Nippon Becton Dickinson Company, Ltd.)

Room 14 (4F G418+G419) / Web Room 14

- 8:00~8:50 **BS6**
  Aiming for further improvement of living! What we can from NESIBLA trying
  Speakers: Tatsuo Ichinohe
  Takashi Shiina
  Chair: Ryoji Kobayashi
  (VERITAS CO.)
- 11:30~12:20 **LS28**
  Treatment of acute GVHD with MSC
  Speaker: Murata Makoto
  Chair: Michihiro Hidaka
  (UCR Pharmaceuticals Co., Ltd.)

Poster / 1F G1 ～ G4

- 9:00~16:15 Poster viewing
- 16:15~17:00 **Poster Presentation** P.126
- Closing Remarks
- 17:05~18:00 **Poster removal**

Exhibition / 1F G1 ～ G4

- 9:00~14:40 Exhibition

Poster Presentation

P2-1～P2-7	Transplant Outcomes 1
P4-1～P4-5	Transplant Outcomes 2
P6-1～P6-6	Transplant Outcomes 3
P8-1～P8-5	Conditioning Regimens 1
P10-1～P10-5	Transplant Outcomes 6
P12-1～P12-6	Transplant Immunity
P14-1～P14-6	Transplant Outcomes/Minimal Residual Disease and Relapse 2
P16-1～P16-4	Infection 1
P18-1～P18-6	Infection 3
P20-1～P20-5	Child-specific Transplant Disease 2
P22-1～P22-6	Child-specific Transplant Disease 3
P24-1～P24-5	Immunotherapy/Cell therapy/Gene therapy 2
P26-1～P26-6	Early Complications 1
P28-1～P28-4	Stem Cell Mobilization and Harvest 2
P30-1～P30-5	Follow-up and QOL/Late Complications
P32-1～P32-6	Late Complications 2
P34-1～P34-6	Early Complications 2

Nursing Poster Presentation

NurseP3-1～NurseP3-6	Follow-up and QOL 2
NurseP4-1～NurseP4-2	Team approach
NurseP6-1～NurseP6-5	Nursing/Education 2
NurseP7-1～NurseP7-5	Nursing/Education 3